Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study

Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study

Abstract Background Currently there is no standard therapy recommended for second‐line treatment for thymic carcinoma. Our study compared multidrug chemotherapy, single‐agent chemotherapy, and PD‐1 inhibitors in patients diagnosed with advanced thymic carcinoma who had previous platinum‐based chemot...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Wang, Xuanye Zhang, Dan Tian, Sen Han, Jie Zhang, Jun Nie, Ling Dai, Weiheng Hu, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Di Wu, Ziran Zhang, Jieran Long, Jian Fang
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
docetaxel
PD‐1 inhibitor
platinum
second‐line therapy
thymic carcinoma
Online Access:https://doi.org/10.1002/cam4.5053
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.5053

Similar Items